{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:57:36Z","timestamp":1783627056123,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Calcium pyrophosphate deposition disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an interleukin-1 inhibitor, is a promising alternative. We aimed to evaluate the efficacy and safety of anakinra in acute CPPD flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched studies from MEDLINE, EMBASE, and the Cochrane Database up until August 2024. The primary outcome was a positive treatment response between Day 3 and Day 5 after anakinra initiation. Secondary outcomes included changes in pain ratings assessed by the visual analogue scales (VAS), C-reactive protein (CRP) levels, tender joint counts (TJCs), swollen joint counts (SJCs), and steroid usage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies were included in our meta-analysis: five observational studies and one randomized controlled trial. A total of 84 patients were included in our analysis. Subjective physician assessments of clinical response were reported in all studies with a combined positive treatment response rate of 76% (95% CI: 61\u201386, I2\u00a0=\u20090%). Our pooled analysis also showed a significant reduction of VAS scores by 48.12\u00a0mm (95% CI: 53.21\u201343.03, I2\u00a0=\u20090%) and CRP levels by 62.09\u00a0mg\/L (95% CI: 97.74\u201326.44, I2\u00a0=\u200977%) from baseline. Reductions of TJC and SJC were also demonstrated: 4.86 (95% CI: 5.48\u20134.23, I2\u00a0=\u20090%) and 3.65 (95% CI: \u221212.53 to 5.22, I2\u00a0=\u200954%), respectively. Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anakinra is a promising alternative treatment for patients with acute CPPD flare as it showed desirable clinical responses and a favourable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf105","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:09:28Z","timestamp":1762520968000},"page":"469-475","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of anakinra for acute calcium pyrophosphate deposition disease flare: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5137-5998","authenticated-orcid":false,"given":"Pannathorn","family":"Nakaphan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Weiss Memorial Hospital , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4189-3621","authenticated-orcid":false,"given":"Somkiat","family":"Phutinart","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5647-346X","authenticated-orcid":false,"given":"Patavee","family":"Pajareya","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1598-6763","authenticated-orcid":false,"given":"Priabprat","family":"Jansem","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Prince of Songkla University , Songkhla ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9961-1075","authenticated-orcid":false,"given":"Sireenada","family":"Sattawatthamrong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-7853","authenticated-orcid":false,"given":"Nattanicha","family":"Chaisrimaneepan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Texas Tech University Health Sciences Center , Lubbock, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-3496","authenticated-orcid":false,"given":"Pim","family":"Jetanalin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of Illinois at College of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-6020","authenticated-orcid":false,"given":"Noppachai","family":"Siranart","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2026041500571517500_ref1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/ard.62.6.513","article-title":"UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte","volume":"62","author":"Neame","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2026041500571517500_ref2","first-page":"981","article-title":"Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study","volume":"27","author":"Ramonda","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2026041500571517500_ref3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3899\/jrheum.190778","article-title":"Acute calcium pyrophosphate crystal arthritis flare rate and risk factors for recurrence","volume":"47","author":"Yates","year":"2020","journal-title":"J Rheumatol"},{"key":"2026041500571517500_ref4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11926-023-01106-9","article-title":"An update on the diagnosis and management of calcium crystal disease","volume":"25","author":"Flood","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2026041500571517500_ref5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026041500571517500_ref6","first-page":"569","article-title":"Calcium pyrophosphate dihydrate crystal deposition: a clinical and laboratory analysis of 91 Thai patients","volume":"82","author":"Louthrenoo","year":"1999","journal-title":"J Med Assoc Thail"},{"key":"2026041500571517500_ref7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.31138\/mjr.261123.afr","article-title":"Anakinra for refractory pseudogout in patients with end-stage renal disease on haemodialysis","volume":"35","author":"Antoniadou","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"2026041500571517500_ref8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","article-title":"The challenges of gout management in the elderly","volume":"28","author":"Stamp","year":"2011","journal-title":"Drugs Aging"},{"key":"2026041500571517500_ref9","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2026041500571517500_ref10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11926-013-0398-z","article-title":"Anti-interleukin-1 therapy in the management of gout","volume":"16","author":"Schlesinger","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2026041500571517500_ref11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","article-title":"Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review","volume":"25","author":"Schlesinger","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026041500571517500_ref12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"2026041500571517500_ref13","doi-asserted-by":"crossref","first-page":"105088","DOI":"10.1016\/j.jbspin.2020.105088","article-title":"Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: a randomized controlled double-blinded pilot study","volume":"88","author":"Dumusc","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2026041500571517500_ref14","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3899\/jrheum.180393","article-title":"Utility of anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a veterans affairs medical center","volume":"46","author":"Desmarais","year":"2019","journal-title":"J Rheumatol"},{"key":"2026041500571517500_ref15","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s10067-023-06573-0","article-title":"A single-centre retrospective case series of anakinra for incident calcium pyrophosphate deposition disease","volume":"42","author":"Lian","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026041500571517500_ref16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis","volume":"79","author":"Molt\u00f3","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2026041500571517500_ref17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint Bone Spine"},{"key":"2026041500571517500_ref18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","article-title":"Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: A retrospective study of 33 cases","volume":"38","author":"Thomas","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026041500571517500_ref19","doi-asserted-by":"crossref","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front Immunol"},{"key":"2026041500571517500_ref20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500571517500_ref21","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026041500571517500_ref22","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40744-021-00335-7","article-title":"Features and outcomes of microcrystalline arthritis treated by biologics: a retrospective study","volume":"8","author":"Doar\u00e9","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2026041500571517500_ref23","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026041500571517500_ref24","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.2001.281.1.C1","article-title":"Inorganic pyrophosphate generation and disposition in pathophysiology","volume":"281","author":"Terkeltaub","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026041500571517500_ref25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/1529-0131(200105)44:5<1071::AID-ANR187>3.0.CO;2-3","article-title":"Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification","volume":"44","author":"Johnson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026041500571517500_ref26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrrheum.2010.182","article-title":"Pathophysiology of articular chondrocalcinosis\u2014role of ANKH","volume":"7","author":"Abhishek","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026041500571517500_ref27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/ard.42.Suppl_1.27","article-title":"Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals","volume":"42","author":"Caswell","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"2026041500571517500_ref28","doi-asserted-by":"crossref","first-page":"10364","DOI":"10.1073\/pnas.92.22.10364","article-title":"Interleukin 1 beta suppresses transforming growth factor-induced inorganic pyrophosphate (PPi) production and expression of the PPi-generating enzyme PC-1 in human chondrocytes","volume":"92","author":"Lotz","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041500571517500_ref29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.semarthrit.2021.04.019","article-title":"Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: a framework paper by the OMERACT CPPD working group","volume":"51","author":"Cai","year":"2021","journal-title":"Semin Arthritis Rheum"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf105\/65246211\/roaf105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/469\/65246211\/roaf105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/469\/65246211\/roaf105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:24Z","timestamp":1776229044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/469\/8317148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf105","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,8]]}}}